Quarterly report · Q2
9273.TEDINET S100SVUE
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.4bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.2bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥29.6bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥27.6bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.7bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥7.5bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥22.0bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥19.6bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.0bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.4bn | at 2022-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥518m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥644m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥304m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥120m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥639m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥812m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥600m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.46 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.34 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.19 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.9 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 74.2% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥38m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥7.9bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥7.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.0bn |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥12.3bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥11.4bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | ¥2.4bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | ¥22m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥8.1bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥761m |
| —segment total | revenue | 2022-07-01 → 2022-12-31 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-12-31 | ¥11.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| —segment total | segment profit | 2022-07-01 → 2022-12-31 | ¥2.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 493
| Item | Context | Value | Unit |
|---|---|---|---|
| Electronically recorded obligations operating cl | Prior1YearInstant | 686818000 | JPY |
| Electronically recorded obligations operating cl | CurrentQuarterInstant | 978432000 | JPY |
| Short term loans payable | Prior1YearInstant | 850000000 | JPY |
| Short term loans payable | CurrentQuarterInstant | 850000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 349904000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | 373904000 | JPY |
| Income taxes payable | Prior1YearInstant | 810011000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 887768000 | JPY |
| Provision for bonuses | Prior1YearInstant | 48558000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 35338000 | JPY |
| Other cl | Prior1YearInstant | 984618000 | JPY |
| Other cl | CurrentQuarterInstant | 666396000 | JPY |
| Current liabilities | Prior1YearInstant | 5233914000 | JPY |
| Current liabilities | CurrentQuarterInstant | 5512247000 | JPY |
| Long term loans payable | Prior1YearInstant | 1941288000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 1766336000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 1460000 | JPY |
| Deferred tax liabilities | CurrentQuarterInstant | 4112000 | JPY |
| Provision for directors retirement benefits | Prior1YearInstant | 137624000 | JPY |
| Provision for directors retirement benefits | CurrentQuarterInstant | 144138000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 135597000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 150163000 | JPY |
| Other ncl | Prior1YearInstant | 91119000 | JPY |
| Other ncl | CurrentQuarterInstant | 79999000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 2307090000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 2144749000 | JPY |
| Liabilities | Prior1YearInstant | 7541004000 | JPY |
| Liabilities | CurrentQuarterInstant | 7656997000 | JPY |
| Capital stock | Prior1YearInstant | 522277000 | JPY |
| Capital stock | CurrentQuarterInstant | 522277000 | JPY |
| Capital surplus | Prior1YearInstant | 205828000 | JPY |
| Capital surplus | CurrentQuarterInstant | 205828000 | JPY |
| Retained earnings | Prior1YearInstant | 20172089000 | JPY |
| Retained earnings | CurrentQuarterInstant | 21259972000 | JPY |
| Treasury stock | Prior1YearInstant | -407000 | JPY |
| Treasury stock | CurrentQuarterInstant | -407000 | JPY |
| Shareholders equity | Prior1YearInstant | 20899787000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 21987670000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 11915000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 27090000 | JPY |
| Deferred gains or losses on hedges | Prior1YearInstant | 11785000 | JPY |
| Deferred gains or losses on hedges | CurrentQuarterInstant | -29165000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 23700000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | -2074000 | JPY |
| Net assets | Prior1YearInstant | 20923488000 | JPY |
| Net assets | CurrentQuarterInstant | 21985595000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 28464493000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 29642592000 | JPY |
| Net sales | Prior1YTDDuration | 11166974000 | JPY |
| Net sales | CurrentYTDDuration | 11382942000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |